Segarra V, Crespo M I, Pujol F, Beleta J, Doménech T, Miralpeix M, Palacios J M, Castro A, Martinez A
Almirall Prodesfarma Research Center, Barcelona, Spain.
Bioorg Med Chem Lett. 1998 Mar 3;8(5):505-10. doi: 10.1016/s0960-894x(98)00058-4.
A 4-centre PDE4 pharmacophore search has been carried out in several 3D-databases containing compounds belonging to different therapeutic areas. Losartan, an angiotensin-II antagonist, has been identified as a new lead compound for developing PDE4 inhibitors. New families of compounds derived from losartan has been synthesized and their PDE inhibition has been measured.
